Active Ingredient History

NOW
  • Now
Milrinone, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. Milrinone inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, Milrinone also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. Milrinone is indicated for the treatment of congestive heart failure. Milrinone was marketed under the brand name Primacor.   NCATS

  • SMILES: CC1=C(C=C(C#N)C(=O)N1)c2ccncc2
  • InChIKey: PZRHRDRVRGEVNW-UHFFFAOYSA-N
  • Mol. Mass: 211.22
  • ALogP: 1.62
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.4020 - $27.5930
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1,6-dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile | corotrop | corotrope | milrinona | milrinone | milrinone lactate | milrinonum | primacor | win-472032 | win-47203-2

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue